IBM's 2028 Quantum Bet: Real Business or Just a $2 Billion Halo?

IBM still has to justify quantum with today's numbers

IBM's quantum story may matter a lot in the future, but the stock still has to live on the current business.

For shareholders, the scoreboard is familiar. Krishna is still guiding to full-year constant currency revenue growth in the range of 4% to 5%, with free cash flow expected to increase by about $1 billion year over year. The message is plain: investors want evidence of paying demand and year-end cash, not just future promise.

That is the core tension. Management is asking investors to look at a long-term opportunity while the company is still judged on present results. And the timeline is not next quarter. Krishna has said quantum should start having a measurable impact on revenue and earnings by 2028 or 2029, with much larger value coming later in the decade. That makes quantum a long-horizon bet, not a near-term earnings driver.

The investor question, then, is straightforward: is IBM early enough on quantum to warrant attention now, without losing focus on the software, infrastructure, consulting, and cost discipline driving the business today?

IBM's quantum advantage claim is more than a speed demo

Start with the technical claim, then strip out the marketing language. IBM and Algorithmiq say they have shown quantum advantage with verified results. In plain English, IBM's system did not simply complete certain tasks more efficiently than leading classical computers; it also produced answers that could be checked and confirmed. That is a meaningful distinction, because raw speed can be a lab flex, while verified correctness is closer to a practical utility test.

What commercial traction would actually look like

The go-to-market setup is already partly in place: IBM already lets businesses use them today via the cloud. That matters because enterprises do not need to buy a quantum system outright. They can test workloads, compare outcomes, and decide whether the tool helps solve a hard problem better, faster, or cheaper.

Krishna has said the research uncovered behaviors in materials that conventional computing had not revealed, with possible downstream payoff in areas such as batteries, advanced materials, fusion energy, and medicines. That fits the kinds of problems where quantum is most often expected to matter: drug discovery, materials science, and difficult optimization tasks. If customers in those fields start seeing useful results, the next step is simple: they budget for it, use it again, and the story moves from lab success toward commercial relevance.

The timing still fails the smell test

A clean technical demonstration is still not the same thing as a busy parking lot. IBM's own timeline says quantum should begin to have a measurable impact on revenue and earnings by 2028 or 2029. Until that happens, it makes more sense to treat quantum as optionality rather than something to underwrite into the stock today.

The risk is not that the science is fake. The risk is that the commercial queue stays thin for too long. Until verified results turn into repeatable customer usage, IBM's quantum story looks more like a halo than a valuation driver.

U.S. funding makes the story easier to believe

The setup just became a little easier to sell.

IBM shares have risen 12% after the U.S. government said it would invest $2 billion in quantum development. That does more than improve the narrative. It shifts quantum from fringe science toward strategic national investment. IBM is also planning to match the government's $1 billion contribution with its own capital.

Why the Albany facility matters

The new money is going to a dedicated quantum chip manufacturing facility in Albany. That matters because it is real infrastructure, not just a press release. It gives IBM a place to refine hardware, build manufacturing know-how, and strengthen capabilities that could be harder for smaller rivals to match.

The government also plans to take minority ownership in nine quantum computing companies. That is unusual, and it signals that Washington sees this as a strategic race rather than a passing tech trend. For IBM, that adds credibility and resources to the quantum story, even if it still falls short of proving commercial traction.

Funding helps, but customers still have to close the loop

Public funding can ease some execution pressure around equipment, talent, and build-out. It does not, by itself, put finished products in customers' hands or prove that enterprises will pay for the output. A prestige project can still be a prestige project.

So the bull case gets cleaner, but the scoreboard stays the same. Investors should watch for signs the money is turning into real business formation:

• Visible progress at the Albany facility.
• Evidence that IBM's cloud access is leading to repeat customer usage.
• Clear use cases where clients can state the practical value in plain English.
• Any management disclosure that shows quantum is becoming more than a headline.

That is the real hinge now. Government backing makes the story more believable. Only customers can make it a business.

The practical investor stance is respect, not euphoria

The practical call is to respect the story, but not pay for it too early. The window that matters is the run-up to 2028 or 2029. If IBM shows real progress before then, the stock can keep earning attention. If not, quantum should remain a halo, not the valuation.

What would strengthen the case before 2028

The bull case gets more credible if Albany starts to look like capability building rather than a prestige project. That means visible progress at the dedicated quantum chip manufacturing facility in Albany, supported by both government backing and IBM's own capital. It also means moving from lab wins to customer wins: IBM has already demonstrated quantum advantage with verified results, and businesses can already access systems via the cloud. The next step is simpler and harder at the same time-getting large-scale customers to move from testing to real workloads.

• Albany: construction momentum, chip-capacity progress, and evidence the site is sharpening IBM's hardware edge.
• Industry wins: names and use cases that show enterprises see real utility, not just research interest.
• Revenue disclosure: management starts separating early quantum traction from the broader innovation story.
• Testing to production: customers shift from trial access to repeated, budgeted usage.

Bulls want those markers because they would show that the path to measurable impact is being built, not just described. Bears have the simpler rebuttal: if the core business wobbles while the broader queue still starts with delayed capital spending projects, investors should be careful about underwriting a science-project narrative. Krishna's warning still matters here-those deals were postponed, not canceled. That is recoverable, but only if the base business stays solid.

My take: keep IBM on the watchlist, not in the 'quantum winner' bucket yet. By the end of this decade, Krishna says the opportunity could be enormous, with a trillion dollars of value by the late 2030s. But right now, the test is old-fashioned: can investors see real demand, or is this still a promising research story with a long road to monetization?